Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

Novel piericidin antitumor antibiotics reported by Japanese and Chinese researchers

Nov. 8, 1996

Potent inhibitor of HSV RR subunit association selected by Bio-Mega/Boehringer Ingelheim

Nov. 8, 1996

Antiarrhythmic 1,4-benzodiazepine from Merck

Nov. 1, 1996

Safer antiarrhythmic agent reported by Canadian researchers

Nov. 1, 1996

Na+ channel inhibitor as cardioprotectant

Nov. 1, 1996

Tyrosine kinase inhibitor for restenosis

Nov. 1, 1996

Nonpeptide NK1/NK2 antagonist identified by Merck & Co.

Nov. 1, 1996

NK1/NK2 antagonist research at Hoechst Marion Roussel

Nov. 1, 1996

Dual H1/NK1 antagonists as potential antiallergics

Nov. 1, 1996

Third-generation ultrasound contrast agent from Sonus

Nov. 1, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...